AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
AstraZeneca entered into a multimillion-dollar licensing deal Monday giving it worldwide exclusive rights to develop and commercialize an oral therapy under development as a potential treatment for chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases.
Under the financial terms of the deal, AstraZeneca (NYSE: AZN) will make an upfront payment of $2 million to C4X Discovery Holdings (AIM: C4XD), a drug discovery company with offices in Manchester and London, …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: AstraZeneca | Chronic Obstructive Pulmonary | Health Management | Pharmaceuticals | Respiratory Medicine